Pramodini Medicare IPO GMP today is Rs 0. Investors can use this GMP along with price band and subscription status for a better IPO review.
Closed
SME IPO
PRAMODINI
Pramodini Medicare IPO GMP, Subscription & Allotment Status Today
Pramodini Medicare Limited is an Indian diagnostic service provider offering a comprehensive range of technology-enabled services, including radiology, clinical laboratory testing, and nuclear medicine. The company serves public and private hospitals, government Public Sector Undertakings (PSUs), and medical colleges across tier I, II, and III cities. Its core offerings are divided into three segments: Radiology (MRI, CT scans, ultrasound), Clinical Laboratory (pathology, microbiology, immunology), and Nuclear Medicine (PET-CT and nuclear therapy). Additionally, it operates a 24×7 teleradiology service from its registered office in Vijayawada. Pramodini Medicare generates revenue by providing routine and specialized tests for prediction, early detection, and disease monitoring. The business uniquely operates across four key models: Public-Private Partnerships (PPP) with government hospitals, Private-Private Partnerships, strategic alliances with PSUs, and standalone private centres. This diversified approach enables the company to deliver widespread preventative and diagnostic healthcare solutions across India.
- Price Band
- ₹110.00 - ₹118.00
- Lot Size
- 1,200 Shares
- Bidding Closes
- 14 Aug 2026
- Listing Date
- 19 Aug 2026
Current GMP Status
₹0
+0% vs upper band
Est. Listing Gain
+0.00%
Last Trend
13 Aug 2026
Listing Price
Est. ₹118
Retail Entry
₹2,83,200
IPO Details
Complete IPO information
| Current GMP | ₹0 |
|---|---|
| Estimated Listing Gain | +0.00% |
| Price Band | ₹110.00 - ₹118.00 |
| Issue Price | Approx ₹118.00 Crores |
| Listing Price | Est. ₹118 |
| Lot Size | 1,200 Shares |
| Issue Type | SME |
| Registrar | TBA |
| Exchange | NSE, BSE |
| Retail Quota | TBA |
| Overall Subscription | 3.87x |
| Listing Date | 19 Aug 2026 |
| Minimum Investment | ₹2,83,200 |
Demand Tracker
Subscription Status
| Category | Shares Reserved | Shares Applied | Subscription (x) |
|---|---|---|---|
| QIB | 11.71 | 42.83 | 3.66x |
| NII | 9.60 | 47.59 | 4.96x |
| Retail | 20.23 | 70.51 | 3.49x |
| Overall Subscription | 41.54 | 160.93 | 3.87x |
Analysis
IPO Snapshot & Investor Takeaways
At the upper end of its price band, Pramodini Medicare is priced at ₹118 per share. With a minimum lot size of 1,200 shares, a retail investor applying for one lot would need approximately ₹2,83,200 to participate in this SME issue.
The latest recorded Grey Market Premium for Pramodini Medicare stands at ₹0, implying an estimated listing gain of around 0.00% over the issue price if it holds until listing. GMP reflects informal grey-market sentiment rather than a guaranteed outcome, and can change at any point until the day of listing.
As of the latest update, Pramodini Medicare's IPO was subscribed 3.87x overall, with a category-wise breakdown of Retail 3.49x, QIB 3.66x, NII 4.96x.
Among the strengths highlighted in Pramodini Medicare's IPO documents: The business model spans PPP, private hospitals, PSUs, and standalone centres.; The diagnostic network grew from 1 centre in FY15 to 16 centres today..
Investors should also weigh the risk factors Pramodini Medicare has disclosed, including: High dependence on government PPP MOUs subject to non-renewal or delayed payments..
SME IPOs list on the dedicated SME platform of BSE/NSE. They usually involve smaller issue sizes and a higher per-lot investment than Mainboard issues, with comparatively lower institutional participation.
Timeline
IPO roadmap at a glance
✓
Bidding Opens
12 Aug 2026
✓
Bidding Closes
14 Aug 2026
03
Allotment Next
17 Aug 2026
04
Listing
19 Aug 2026
Grey Market Premium
Daily GMP status
Trend chart builds up as more daily GMP snapshots are recorded.
| Date | GMP | Change | Gain |
|---|---|---|---|
| 13 Aug 2026 | ₹0.00 | - | 0.00% |
Swipe to see more →
Market Lot
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 Lot | 2,400 | ₹2,83,200 |
| Retail Maximum | 2 Lot | 2,400 | ₹2,83,200 |
| S-HNI Minimum | 3 Lot | 3,600 | ₹4,24,800 |
| S-HNI Maximum | 7 Lot | 8,400 | ₹9,91,200 |
| B-HNI Minimum | 8 Lot | 9,600 | ₹11,32,800 |
Swipe to see more →
Fund Utilization
Objects of the Issue & Official Documents
Issue Notes
Important takeaways before applying
Strengths
- The business model spans PPP, private hospitals, PSUs, and standalone centres.
- The diagnostic network grew from 1 centre in FY15 to 16 centres today.
- Offers specialized services across radiology, clinical laboratory, and nuclear medicine.
- Revenue grew significantly from ₹3,522.95 lakhs in FY24 to ₹6,228.75 lakhs in FY26.
- Leverages public health infrastructure through extensive government MOUs.
Risks
- High dependence on government PPP MOUs subject to non-renewal or delayed payments.
- Focus on capital-intensive radiology exposes the firm to equipment and regulatory risks.
- Over 60% revenue concentration in Andhra Pradesh creates geographic risk.
- Loss of top institutional clients could severely impair revenue and profitability.
- Past statutory filing delays and non-compliances expose the firm to regulatory penalties.
Analysis
Pramodini Medicare IPO Details
The Pramodini Medicare IPO is a Book Building Issue with a total issue size of approximately ₹69.04 crores. The public issue comprises a fresh issue of approximately ₹63.14 crores along with an Offer for Sale (OFS) of approximately 5,00,400 equity shares.
The IPO opens for subscription on August 12, 2026 and closes on August 14, 2026. The company has fixed a price band of ₹110 to ₹118 per equity share, with a face value of ₹10 per share. The equity shares are proposed to be listed on the NSE SME platform.
| Particular | Details |
|---|---|
| IPO Open Date | August 12, 2026 |
| IPO Close Date | August 14, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹110 to ₹118 Per Share |
| Issue Size | Approx ₹69.04 Crores |
| Fresh Issue | Approx ₹63.14 Crores |
| Offer for Sale (OFS) | Approx 5,00,400 Equity Shares |
| Issue Type | Book Building Issue |
| IPO Listing | NSE SME |
Note: Pramodini Medicare's IPO is an SME public issue. Investors should consider the company's financial performance, issue valuation, business prospects, peer comparison, and associated risks before making an investment decision.
Analysis
Pramodini Medicare IPO Reservation
The Pramodini Medicare IPO has allocated shares across Anchor Investors, Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), and Retail Individual Investors. The reservation structure determines the number and percentage of shares available for each investor category.
Anchor investors have been allocated 13,60,800 shares, representing 23.26% of the issue. The QIB category excluding anchor investors has been allocated 11,71,200 shares, while 9,60,000 shares are available for NIIs. Retail investors have been offered 20,23,200 shares, representing 34.58% of the issue.
| Investor Category | Shares Offered | Reservation (%) |
|---|---|---|
| Anchor Investor | 13,60,800 Shares | 23.26% |
| Qualified Institutional Buyers (QIB) (Ex. Anchor) | 11,71,200 Shares | 20.02% |
| Non-Institutional Investors (NII) | 9,60,000 Shares | 16.41% |
| Retail Individual Investors (RII) | 20,23,200 Shares | 34.58% |
Note: The above table presents the category-wise IPO reservation details. Final allotment to investors will depend on the subscription received in each category and the basis of allotment finalized after the IPO closes.
Analysis
Pramodini Medicare IPO Anchor Investors
The Pramodini Medicare IPO anchor investor bidding was scheduled for August 11, 2026, one day before the public issue opened for subscription. Anchor investors form part of the institutional allocation and participate in the IPO before the issue becomes available to other investor categories.
The final anchor investor list, number of shares allocated, anchor issue size, and applicable lock-in dates can be updated once the complete anchor allocation information is available.
| Particular | Details |
|---|---|
| Anchor Bidding Date | August 11, 2026 |
| Anchor Investors List | To be Updated |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| Lock-in Period End Date – 50% Shares (30 Days) | 2026 |
| Lock-in Period End Date – Remaining 50% Shares (90 Days) | 2026 |
Note: The anchor investor names, final shares offered, anchor size, and exact 30-day and 90-day lock-in expiry dates should be updated once the final anchor allocation details are available.
Analysis
Pramodini Medicare IPO Dates
The Pramodini Medicare IPO opens for subscription on August 12, 2026 and closes on August 14, 2026. After the subscription period ends, the basis of allotment is scheduled to be finalized on August 17, 2026.
Refunds for unsuccessful applicants are expected to be initiated on August 18, 2026. Successful applicants are also expected to receive the allotted equity shares in their demat accounts on the same date. Pramodini Medicare shares are proposed to be listed on the NSE SME platform on August 19, 2026.
| IPO Event | Date |
|---|---|
| IPO Open Date | August 12, 2026 |
| IPO Close Date | August 14, 2026 |
| Basis of Allotment | August 17, 2026 |
| Refunds | August 18, 2026 |
| Credit to Demat Account | August 18, 2026 |
| IPO Listing Date | August 19, 2026 |
Note: The above dates represent the proposed Pramodini Medicare IPO schedule. The timeline may be revised by the company, registrar, or stock exchange if required.
Analysis
Pramodini Medicare IPO Promoters and Holding Pattern
The promoters of Pramodini Medicare are Dr. Chalasani Kuldeep Kumar, Dr. Chalasani Kavitha, Ms. Chalasani Durga Aashritha and M/s. Sri Ram Medicare Private Limited. Before the IPO, the promoter and promoter group collectively hold 85.71% of the company's equity share capital.
Following the IPO, the promoter and promoter group's shareholding is expected to decline to 62.64%, while the shareholding of other investors is expected to increase from 14.29% to 37.36%. The company's total equity shares are expected to increase from 1,66,94,795 shares before the IPO to 2,20,45,595 shares after the issue.
Promoters of Pramodini Medicare
- Dr. Chalasani Kuldeep Kumar
- Dr. Chalasani Kavitha
- Ms. Chalasani Durga Aashritha
- M/s. Sri Ram Medicare Private Limited
| Particular | Pre IPO Shares | Pre IPO % Shares | Post IPO Shares | Post IPO % Shares |
|---|---|---|---|---|
| Promoter and Promoter Group | 1,43,09,477 | 85.71% | 1,38,09,077 | 62.64% |
| Others* | 23,85,318 | 14.29% | 82,36,518 | 37.36% |
| Total | 1,66,94,795 | 100% | 2,20,45,595 | 100% |
Note: The above table presents the pre-IPO and proposed post-IPO shareholding pattern of Pramodini Medicare. The promoter group's holding is expected to decrease from 85.71% before the issue to 62.64% after completion of the IPO.
Analysis
Pramodini Medicare IPO Objects of the Issue & Utilisation of Proceeds
Pramodini Medicare intends to utilise a major portion of the fresh issue proceeds towards capital expenditure for purchasing medical equipment. The equipment is proposed to be deployed across the company's existing as well as proposed diagnostic centres, supporting the expansion and strengthening of its diagnostic infrastructure.
The company plans to allocate approximately ₹45.15 crores towards the purchase of medical equipment. A portion of the proceeds will also be available for general corporate purposes and unidentified inorganic acquisitions, providing flexibility for future business requirements and potential expansion opportunities.
| Purpose | Amount |
|---|---|
| Funding of capital expenditure for purchase of medical equipment towards existing and proposed diagnostic centres | ₹45.15 Crores |
| General corporate purposes and unidentified inorganic acquisition | ₹- |
Note: The above utilisation represents the proposed deployment of the IPO proceeds. Actual expenditure may vary depending on equipment procurement, expansion requirements, acquisition opportunities, business conditions, and applicable regulatory provisions.
Analysis
Pramodini Medicare About IPO
Pramodini Medicare Limited, founded in 2000, is one of the leading diagnostic services providers in India across radiology, clinical laboratory, and nuclear medicine segments. Its service portfolio includes radiology services such as MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, DEXA scan, and interventional radiology; clinical laboratory services including haematology, microbiology, immunology, pathology, and biochemistry; and nuclear medicine services such as PET-CT, SPECT, and nuclear therapy.
Pramodini Medicare operates diagnostic centres through Public-Private Partnerships (PPP), Private-Private Partnerships (Pvt-Pvt), Strategic Partnerships with PSUs, Standalone Diagnostic Centres, and Location-Specific Agreements. The firm has its presence across Vijayawada, Hyderabad, Kurnool, Kapada, Tirupati, Varanasi, Prayagraj, and many others.
Analysis
Pramodini Medicare IPO Company Financial Report
Pramodini Medicare has reported growth in both revenue and profitability during the period from FY2024 to FY2026. Revenue increased from ₹35.79 crores in FY2024 to ₹38.55 crores in FY2025 and further rose to ₹63.38 crores in FY2026.
The company's Profit After Tax (PAT) also improved consistently, increasing from ₹7.14 crores in FY2024 to ₹11.14 crores in FY2025 and ₹17.38 crores in FY2026. Meanwhile, total assets expanded from ₹48.78 crores in FY2024 to ₹93.62 crores in FY2026.
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2024 | ₹35.79 Cr. | ₹25.72 Cr. | ₹7.14 Cr. | ₹48.78 Cr. |
| 2025 | ₹38.55 Cr. | ₹22.80 Cr. | ₹11.14 Cr. | ₹56.45 Cr. |
| 2026 | ₹63.38 Cr. | ₹40.08 Cr. | ₹17.38 Cr. | ₹93.62 Cr. |
Amount in ₹ Crores: The above table summarizes Pramodini Medicare's revenue, expenses, Profit After Tax (PAT), and total assets from FY2024 to FY2026. Investors should consider these financial trends together with the company's IPO valuation, margins, debt position, business expansion plans, and future growth prospects.
Analysis
Pramodini Medicare IPO Valuation – FY2026
The Pramodini Medicare IPO valuation can be assessed through key financial indicators such as Earnings Per Share (EPS), Return on Equity (ROE), Return on Capital Employed (ROCE), EBITDA Margin, PAT Margin, Return on Net Worth (RoNW), and Net Asset Value (NAV). These metrics provide an overview of the company's profitability, capital efficiency, leverage, and financial position.
For FY2026, Pramodini Medicare reported an EPS of ₹10.41, ROE of 39.08%, and ROCE of 34.66%. The EBITDA margin stood at 49.61%, while the PAT margin was 27.90%. The company reported a debt-to-equity ratio of 0.34 and a Net Asset Value of ₹31.84 per share.
| KPI | Values |
|---|---|
| ROE | 39.08% |
| ROCE | 34.66% |
| EBITDA Margin | 49.61% |
| PAT Margin | 27.90% |
| Debt to Equity Ratio | 0.34 |
| Earning Per Share (EPS) | ₹10.41 (Basic) |
| Price / Earnings (P/E) Ratio | N/A |
| Return on Net Worth (RoNW) | 32.69% |
| Net Asset Value (NAV) | ₹31.84 |
Note: The above valuation indicators are based on FY2026 financial information. Investors should compare these metrics with the IPO price band, peer-group valuations, historical financial performance, business growth, debt levels, and industry outlook before making an investment decision.
Analysis
Pramodini Medicare IPO Peer Group Comparison
The peer group comparison of Pramodini Medicare helps investors evaluate the company's financial position against listed companies operating in the diagnostics and healthcare services industry. Key parameters such as Earnings Per Share (EPS), Price-to-Earnings (P/E) Ratio, Return on Net Worth (RoNW), Net Asset Value (NAV), and income can be considered while assessing the IPO valuation.
Pramodini Medicare's peer group includes Invicta Diagnostic Limited, Krsnaa Diagnostics Limited, and Star Imaging & Path Labs Limited. Investors should consider differences in operating scale, diagnostic network, profitability, growth rates, and business models when comparing these companies.
| Company | EPS | P/E Ratio | RoNW (%) | NAV (₹) | Income |
|---|---|---|---|---|---|
| Invicta Diagnostic Limited | 4.90 | 13.62 | 9.76% | 39.71 | – Cr. |
| Krsnaa Diagnostics Limited | 31.30 | 16.74 | 10.35% | 302.23 | – Cr. |
| Star Imaging & Path Labs Limited | 11.05 | 7.87 | 16.58% | 66.65 | – Cr. |
Note: Peer group figures should be used as comparative benchmarks and not as the sole basis for an investment decision. Investors should also consider Pramodini Medicare's IPO valuation, financial growth, profitability margins, debt position, business expansion plans, and industry-specific risks.
Analysis
IPO Lead Managers aka Merchant Bankers
- Smart Horizon Capital Advisors Pvt.Ltd.
FAQ
Pramodini Medicare IPO FAQs
Pramodini Medicare IPO price band is Rs 110.00 to Rs 118.00. Check the latest issue price, lot size and GMP together before applying.
Pramodini Medicare IPO open date is 12 Aug 2026, close date is 14 Aug 2026, and listing date is 19 Aug 2026.
Pramodini Medicare IPO lot size is 1,200 shares. The minimum retail investment is Rs 2,83,200.
Pramodini Medicare is classified as a SME IPO. This helps investors quickly understand the issue category and exchange segment.
Pramodini Medicare IPO subscription status currently shows Retail 3.49x, QIB 3.66x, NII 4.96x, Overall 3.87x.
Pramodini Medicare Limited is an Indian diagnostic service provider offering a comprehensive range of technology-enabled services, including radiology, clinical laboratory testing, and nuclear medicine. The company serves public and private hospitals, government Public Sector Undertakings (PSUs), and medical colleges across tier I, II, and III cities. Its core offerings are divided into three segments: Radiology (MRI, CT scans, ultrasound), Clinical Laboratory (pathology, microbiology, immunology), and Nuclear Medicine (PET-CT and nuclear therapy). Additionally, it operates a 24×7 teleradiology service from its registered office in Vijayawada. Pramodini Medicare generates revenue by providing routine and specialized tests for prediction, early detection, and disease monitoring. The business uniquely operates across four key models: Public-Private Partnerships (PPP) with government hospitals, Private-Private Partnerships, strategic alliances with PSUs, and standalone private centres. This diversified approach enables the company to deliver widespread preventative and diagnostic healthcare solutions across India.
Pramodini Medicare IPO issue size is 69.04 and the expected allotment date is 17 Aug 2026.
Community discussion
Comments
Share a useful question or insight about Pramodini Medicare.
Leave a comment
Your email address will not be published. All comments and replies are reviewed before appearing.
Keep Exploring
Similar Recent IPOs
Upcoming
SME
Axiom Gas Engineering
Current GMPN/A
Price Band₹50.00 - ₹53.00
Lot Size2,000 Shares
Upcoming
SME
SpectraA Technology Solutions
Current GMPN/A
Price Band₹112.00 - ₹118.00
Lot Size1,200 Shares
Upcoming
SME
Kheria Autocomp
Current GMPN/A
Price Band₹96.00 - ₹101.00
Lot Size1,200 Shares
Open
SME
Vama Wovenfab
Current GMP₹10+2.9%
Price Band₹324.00 - ₹341.00
Lot Size400 Shares
Loading comments...